STAT Plus: Coles-led Cerevel Therapeutics to raise $445 million to develop brain drugs with fewer side effects
Cerevel Therapeutics, a Boston neuroscience company spun out from Pfizer in 2018 and led by the well-known CEO Tony Coles, is going public.
No hay comentarios:
Publicar un comentario